



UvA-DARE (Digital Academic Repository)

Regulation of translesion synthesis polymerases during somatic hypermutation and DNA damage tolerance

Krijger, P.H.L.

Publication date
2011

[Link to publication](#)

Citation for published version (APA):

Krijger, P. H. L. (2011). *Regulation of translesion synthesis polymerases during somatic hypermutation and DNA damage tolerance*. [Thesis, externally prepared, Universiteit van Amsterdam].

General rights

It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).

Disclaimer/Complaints regulations

If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: <https://uba.uva.nl/en/contact>, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.

GENERAL INTRODUCTION

Adapted from: Peter H.L. Krijger, Ursula Storb and Heinz Jacobs.
Error-prone and Error-free Resolution of AID lesions in SHM;
Chapter 6 in DNA deamination and the Immune System. Series on Molecular Medicine,
Vol. 3. London, UK, Imperial College Press, 2010. ISBN -101-84816-592-7.





GENERATION OF HIGH AFFINITY ANTIBODIES

In 1890 it was shown that resistance to diphtheria and tetanus results from the formation of substances that circulate in the blood of immunized animals (Silverstein, 1985). These substances are now known as antibodies and are widely used in the diagnostics and treatment of many different diseases (Nelson et al., 2010). Antibodies consist of two identical immunoglobulin heavy chains and light chains and are produced by B cells, a specialized cell of our immune system (Fig. 1). The amino-terminal or variable region of the antibody is responsible for antigen binding, while the carboxy-terminal or constant region determines the effector function and tissue localisation. As each B cell can only produce antibodies with a single specificity, but an organism can generate antibodies against an unlimited range of antigens, Lederberg proposed over 50 years ago that B cells undergo a high frequency of (genome wide) somatic mutation to create a virtual unlimited antibody repertoire with a size-limited genome (Lederberg, 1959). While antibody diversification is now known to occur initially during early B cell development by V(D)J recombination of the immunoglobulin (Ig) genes (Tonegawa, 1983) (Fig. 1), it has been established that the generation of high affinity antibodies in activated mature B cells critically depends on a continuous neo-Darwinian maturation and evolution of antibody specificities by somatic hypermutation (SHM) of the variable region of Ig genes and antigen-mediated selection. (Di Noia and Neuberger, 2007; Neuberger, 2008). Both SHM and selection take place in germinal centers (GC), highly dynamic structures formed within secondary lymphoid organs shortly after activation of B cells by binding of their antibody to an antigen (Rajewsky, 1996; Victora et al., 2010). In addition to SHM, GC B cells can undergo class switch recombination (CSR) to replace the Ig heavy chain constant region for a downstream constant region (i.e. IgG, IgA or IgE), to generate an antibody with a different effector function. (Stavnezer et al., 2008). Thus, over a short period after first encounter with antigen, low-affinity antibodies specific for the antigen can be transformed into high-affinity antibodies, usually of an IgG, IgA, or IgE isotype.

SHM AND CSR: IT ALL STARTS WITH DNA DEAMINATION

SHM and CSR are initiated by the activation-induced cytidine deaminase (AID), an enzyme found to be differentially expressed in B cells of the GC (Muramatsu et al., 2000). AID deaminates cytosine (C) to uracil (U) within single stranded DNA (Pham et al., 2003; Chaudhuri et al., 2003; Dickerson et al., 2003; Ramiro et al., 2003), showing a preference for WRC motifs (W=A/T, R=purine). As AID targets both DNA strands *in vivo* (Dorner et al., 1998; Milstein et al., 1998), the hotspot motif of antibody hypermutation WRCY (Y=pyrimidine), might be explained by deamination of a substrate that contains overlapping WRC motifs

on opposite DNA strands by different subunits of an AID oligomer (Rogozin and Kolchanov, 1992; Beale et al., 2004). While the primary lesion is restricted to cytosine deamination, SHM occurs equally efficient at G/C and A/T basepairs. During the last decennium, humans, mice, and cell lines carrying defined genetic alterations in DNA repair and DNA damage tolerance elements have revealed detailed insights into the molecular pathways controlling the generation of defined point mutations in hypermutating Ig genes. The combination of these pathways enables hypermutating B cells to generate the entire spectrum of nucleotide substitutions at a rate of one per thousand bases per generation, six




Fig.1. VDJ recombination, SHM and CSR. During early B cell development the primary B cell repertoire is generated by recombination of the V(D)J gene segments encoding for the variable domain of the heavy chain. For simplicity recombination of the VJ genes of the light chain is not depicted. Upon antigen binding, B cells can undergo multiple rounds of somatic hypermutation and selection to increase the affinity of the antibody for the cognate antigen. In addition, B cells can undergo class switch recombination, which involves replacement of the Ig heavy chain constant region for a downstream constant region.

orders of magnitude greater than spontaneous mutagenesis. To establish these point mutations at and around the initial U lesion, B cells proved to be highly creative in transforming established DNA repair pathways into effective mutator pathways. The mutagenic transformation of these faithful repair pathways appears to depend strongly on a family of specialized DNA polymerases with defined error signatures. To date, three main mutation pathways have been identified that contribute to the mutagenic processing of U generated by AID (Figure 2). This chapter focuses on the role of these pathways and present knowledge/models regarding their (in)dependence in establishing specific point mutations. In addition, we here focus on the regulatory aspects controlling the establishment of defined mutations.

DIRECT REPLICATION ACROSS THE URACIL: G/C TRANSITIONS

Besides intentional cytosine deamination of Ig genes by AID in hypermutating B cells, spontaneous cytosine deamination occurs frequently and is one of the most common lesions in our genome. If not removed timely from the genome, a uracil is highly mutagenic. During DNA synthesis a U in the template strand will instruct DNA polymerases to incorporate an Adenine (A), causing G to A and C to T transitions. In agreement with this notion, bacteria defective in removing U from their genome have a high rate of spontaneous G/C to A/T transitions (Duncan and Miller, 1980). First data suggesting a role of this mutation pathway during SHM was provided by the observation that expression of AID in these bacteria resulted in an increase of G/C to A/T transitions (Petersen-Mahrt et al., 2002). The significance of this pathway was further corroborated in mice defective in the removal of U (Shen et al., 2006; Rada et al., 2004). In these mice, the base exchange pattern of mutated Ig genes was extremely compromised, showing only G/C transitions. These data clearly revealed a major pathway in the generation of G/C transition mutations and strongly suggested that the remaining point mutations of the hypermutation spectrum require further modifications of the initial U lesion (Figure 2, left panel). In fact, as outlined below SHM critically depends on two generic DNA repair factors, capable of recognizing U in the DNA, the base excision repair (BER) factor Ung and the mismatch repair (MMR) factor MutS α (Figure 2, middle and right panel, respectively).




Figure 2. The three pathways of SHM downstream of AID. AID deaminates C to U. Three error prone repair pathways can process the U: I.) Left panel: Direct replication across U; a U in the template strand instructs a template T leading to the generation of G/C to A/T transitions (TS). II.) Middle panel: Ung2 dependent SHM; upon removal of the U by Ung2 an abasic site (AP site, indicated by a star) is generated. Replication across this Ung2-dependent, non-instructive AP site generates G/C transitions and transversions (TV). Rev1 generates G to C transversions. Other unknown polymerases (?) generate G/C transversions and possibly transitions. A minority of A/T mutations (~10%) is generated downstream of Ung2 and depend on Pol η and possibly PCNA-Ub. III.) Right panel: MutS α -dependent SHM; the U/G mismatch generated by AID can also be recognized by MutS α . MutS α , an unknown 5' endonuclease and Exo1 generate a large gap. This MutS α /Exo1-dependent gap triggers the Rad6 pathway, leading to monoubiquitination of PCNA (PCNA-Ub), which in turn recruits the A/T mutator Pol η to generate A/T mutations.

UNG DEPENDENT SHM ACROSS AP SITES: G/C TRANSVERSIONS AND TRANSITIONS

1

To maintain the integrity of the genome, U and other highly mutagenic base modifications can effectively be removed by a multistep repair process, known as base excision repair (BER). BER is initiated by a family of highly efficient, partially redundant DNA-glycosylases capable of recognizing and removing modified bases from our genome. DNA-glycosylases catalyze the hydrolysis of the N-glycosidic bond that links the base to the deoxyribose-phosphate backbone. After the base excision step, the DNA duplex now harbors an apurinic or apyrimidinic, i.e. an AP site in its backbone, which is also known as abasic site. The repair of AP sites, the common product of glycosylase action, requires a second class of BER enzymes known as AP endonucleases, APE1 and APE2 in mammals, which generate nicks in the duplex DNA by hydrolysis of the phosphodiester bond immediately 5' to the AP site. In mammalian cells, further processing involves DNA polymerase β (Pol β). Pol β has two enzymatic activities, a large C-terminal DNA polymerase domain and a small N-terminal DNA-deoxy-ribose-phosphodiesterase (dRpase). While the dRpase activity of Pol β makes a second nick to remove the AP deoxyribose, the polymerase activity fills up the single nucleotide gap. While the lack of an intrinsic proof reading activity renders Pol β error prone (1-2 misinsertions per 10000), accuracy might be gained at the level of DNA ligation and postreplicative MMR (Kunkel, 1985; Friedberg et al., 2006). In addition to this short patch BER pathway (1nt), the nature of the DNA glycosylase and/or lesion may require an alternative pathway of BER, known as long patch BER. Long patch BER involves the flap-endonuclease 1 (FEN1), which after displacement of the strand containing the modified base (flap) makes an incision to generate a long single-strand patch (2-8nt). Repair synthesis of this long patch requires components of the replication machinery such as Pol δ and Pol ϵ , the DNA sliding clamp Proliferating Cell Nuclear Antigen (PCNA) as well as DNA ligase 1. Given the accuracy of Pol δ , and Pol ϵ , long patch BER is effective in maintaining genome integrity after base damage. Besides replicative DNA polymerases, Pol β may also contribute to long patch BER, (Podlutzky et al., 2001; Singhal and Wilson, 1993).

In mammals, four DNA glycosylases have been identified that can hydrolyze U from the DNA backbone: Uracil-DNA glycosylase (UNG), SMUG DNA glycosylase (SMUG1), methyl-binding domain glycosylase 4 (MBD4), and thymine DNA glycosylase (TDG) (Krokan et al., 2002). Although redundant in their enzymatic activity *in vitro*, only UNG appears to be essential during SHM (Bardwell et al., 2003; Di Noia et al., 2006; Rada et al., 2004; Rada et al., 2002). Two alternative splice variants of UNG exist, a mitochondrial (UNG1) and a nuclear (UNG2). *Ung* mutant B cells lack most G/C transversions (Rada et al., 2002). These transversions do not depend on Pol β , as Pol β deficient B cells mutate normally (Esposito et al., 2000). The role of the APE endonucleases during SHM is unknown, as APE1



deficiency causes early embryonic lethality (Xanthoudakis et al., 1996). Most likely, during SHM AP sites are not always removed prior to replication or repair synthesis. As AP sites are non-instructive they cause replicative DNA polymerases to stall. To continue DNA synthesis across an AP site specialized polymerases are recruited (see below) that tolerate such blocking lesions and thereby generate G/C transversion as well as transition mutations (Figure 2, middle panel). Besides APE the Mre11/Rad50/Nbs1 (MRN) complex has been proposed to initiate mutagenesis by cleaving AP sites (Larson et al., 2005;Yabuki et al., 2005). As the resulting ends cannot be extended by high-fidelity DNA polymerases, it has now been suggested that error prone DNA polymerases take over to introduce mutations when filling the gap. Future studies in MRN deficient cells should clarify the relevance of this pathway in SHM.

MUTS α DEPENDENT SHM AT MMR GAPS: A/T MUTATIONS

Cytosine deamination in the DNA helix generates a U:G mismatch. Besides BER, the U:G mismatch can be processed by DNA mismatch repair (MMR) (Wilson et al., 2005;Schanz et al., 2009). MMR is an evolutionarily conserved process that normally corrects mismatches that have escaped proofreading during DNA replication. The MMR process involves a complex interplay of MMR-specific proteins with the replication and/or recombination machinery (Jiricny, 1998). MMR is initiated by the binding of the mismatch-recognition factors, MutS α (MSH2/MSH6 complex) to single base mismatches or MutS β (MSH2/MSH3 complex) to insertion/deletion loops that arise during recombination or from replication. Mammalian MMR is proposed to initiate at strand discontinuities, such as nicks or gaps that are distal to the mispair (Modrich, 2006;Schanz et al., 2009) The recruitment of MutL homologues (MutL α : MLH1-PMS2 complex; MutL β : MLH1-PMS1 complex) stabilizes the mismatch-bound MutS α complex and appears to prohibit sliding of MutS. Exonuclease-1 (Exo1) mediated degradation of the error-containing strand depends on an incision 5' of the mismatch. This incision may involve the nuclease activity of PMS2 (Kadyrov et al., 2006) or an alternative nuclease. Once the mismatch is removed, resynthesis of the degraded region by a DNA polymerase, followed by sealing of the remaining nick by DNA ligase, completes the repair process.

Remarkably, given the protective nature of MMR in preventing mutations arising from mismatched non-Watson-Crick base pairs, early studies in mismatch repair mutant mice revealed a selective role of the mismatch recognition complex MutS α as well as Exo1 in establishing somatic mutation at template A/T around the initial U:G mismatch. Interestingly, while MSH2, MSH6 and Exo-1 deficient B cells lack 80-90% of all A/T mutations, the SHM phenotype appears less pronounced

or even normal in B cells lacking other MMR components such as PMS2, MLH1, MLH3 and MSH3 (Rada et al., 1998; Wiesendanger et al., 2000; Bardwell et al., 2004; Martomo et al., 2004; Phung et al., 1998; Phung et al., 1999; Ehrenstein et al., 2001; Winter et al., 1998; Jacobs et al., 1998; Frey et al., 1998). These data suggest that during SHM, selective components of the mismatch repair machinery are required to generate a single strand gap. In contrast to conventional, postreplicative MMR, the gap filling process during SHM appears to employ error prone TLS polymerase(s) that generate predominantly A/T mutations (Figure 2, right panel). At present the identity of the incision maker 5' to the mismatch, which is required for Exo1 is unknown. UNG2/APE has been proposed (Schanz et al., 2009), but given the fact that A/T mutations are mainly unaffected in Ung deficient B cells (Rada et al., 2002; Krijger et al., 2009), alternative uracil glycosylases might take over.

UNG DEPENDENT A/T MUTATIONS AND MUTS α DEPENDENT G/C MUTATIONS

The above mentioned observations have resulted in a model in which there is a strict separation between the MutS α - and Ung-dependent pathways in establishing mutations at template A/T and G/C respectively. However, as Msh2 and Msh6 deficient mice show a more restricted targeting of G/C mutations in the V region (Martomo et al., 2004; Delbos et al., 2007; Frey et al., 1998; Rada et al., 1998), MutS α may also be involved in the generation of G/C mutations. In addition, a significant fraction of A/T mutations (10-20%) are found in MSH2 deficient GC B cells (but not in UNG2/MSH2 double deficient B cells), indicating that UNG2 dependent mutagenesis generates A/T mutations independent of MutS α (Rada et al., 2004). Whether UNG2-dependent A/T mutations are generated during long patch BER, i.e. within the strand containing the AP site, or alternatively during the extension phase of TLS across the AP site is currently unknown. Mice deficient for FEN1 are embryonic lethal, and analysis of B cells from mice expressing a hypomorph variant of FEN1 showed no SHM phenotype (Larsen et al., 2008), conditional knock out mice or deficient cell lines will have to be generated to reveal a function of this pathway in SHM.

TRANSLESION SYNTHESIS DNA POLYMERASES

To explain the unusual high mutation rate of SHM, error prone polymerases were postulated about half a century ago (Brenner and Milstein, 1966). Yet, only during the last two decades the existence of error prone TLS DNA polymerases was revealed. Their characterization *in vitro* and *in vivo* indicated an error rate that

Table 1. DNA polymerases in higher eukaryotes

Family	Pol	Function
A	Poly	Mitochondrial DNA replication
	Pol θ	TLS (?) BER (?)
	Polv	TLS (?)
B	Pol α	Replication priming
	Pol δ	Replication
	Pol ϵ	Replication
	Pol ζ	TLS SHM (? - Reduced mutations in ko)
X	Pol β	BER
	Pol λ	BER NHEJ(V(D)J recombination) TLS (?)
	Pol μ	NHEJ (VJ recombination), TLS (?)
	TdT	V(D)J recombination
	Pol η	TLS SHM (A/T mutations) homologous recombination
Y	Pol ι	TLS
	Rev1	TLS SHM (C>G and G>C)
	Pol κ	TLS NER SHM (Backup Pol η , A/T mutations)

easily matches the one of SHM. In higher eukaryotes, TLS is carried out primarily by the Y family polymerases Pol η , Pol ι , Pol κ and Rev1, the B family member pol ζ (Prakash et al., 2005; Guo et al., 2009). In addition other polymerases have been identified to display TLS activity (Table 1). TLS polymerases share the unique capacity to bypass DNA lesions, i.e. they can continue replication in the presence of noninstructive or misinstructive DNA lesion that otherwise may stall the replicative Pol ϵ and Pol δ . In general, TLS is thought to proceed in a two-step mode (Shachar et al., 2009; Johnson et al., 2000; Ziv et al., 2009) 1.) Incorporation of nucleotide(s) directly opposite of the lesion. 2.) Elongation from the distorted or bulky non-Watson-Crick base pairs by an extender TLS polymerase. A prerequisite for TLS is the lack of proofreading activity by TLS polymerases. Once extended, proofreading proficient high fidelity DNA polymerase cannot detect the tolerated lesion any longer and resumes DNA synthesis. While the capacity of TLS polymerases to accommodate non Watson-Crick base pairs within their catalytic center is beneficial regarding the accurate replication across specific modified bases, it also makes TLS polymerases highly mutagenic when replicating

across undamaged DNA or other lesions (Jansen et al., 2007;Prakash et al., 2005). Since each polymerase displays its own mutagenic signature, alterations in the mutation spectrum can often be attributed retrospectively to the absence of or failure in activating specific polymerases. This preference has been highly beneficial regarding the identification of DNA polymerases involved in SHM.

Pol η

Pol η , a polymerase that is absent or hypomorph in patients with the variant form of Xeroderma Pigmentosum (XP-V) (Johnson et al. 1999)(Masutani et al., 1999b), is highly efficient and error-free when replicating UV-induced cyclobutane pyrimidine dimers (CPDs), the oxidative lesion 8-oxodeoxyguanosine (8-oxo-dG) and cisplatin-induced GG intrastrand crosslinks (Johnson et al., 1999;McCulloch et al., 2004a;Matsuda et al., 2000;Shachar et al., 2009;McCulloch et al., 2004b;Vaisman et al., 2000;Haracska et al., 2000). The observations that XP-V patients are hypersensitive and hypermutable to UV damage, associated with a strong predisposition to skin cancer (Masutani et al., 1999a;Johnson et al., 1999) indicate that at least in the context of UV-induced DNA damage, other TLS polymerases are non-redundant with Pol η activity *in vivo*. In contrast, Pol η is error-prone when replicating undamaged DNA, a feature employed during SHM as indicated by the significant reduction in mutations at A/T base pairs in B cells from XP-V patients (Zeng et al., 2001) and mouse models defective for Pol η (Delbos et al., 2005;Martomo et al., 2005). Consistent with these *in vivo* data, Pol η has a preference to insert mismatched nucleotides opposite template T (Rogozin et al., 2001). These data suggest that Pol η is required to generate A/T mutations downstream of Mut α . In addition to its role downstream of Mut α , Pol η is responsible for the remaining A/T mutations downstream of UNG2, as deduced from SHM analysis in MSH2 and MSH2/Pol η -deficient mice (Delbos et al., 2007).

Pol κ

In vitro experiments have shown that purified Pol κ efficiently and accurately bypasses benzo[a]pyrene-guanine (BP-G) adducts (Zhang et al., 2000). The observation that Pol κ deficient cells, are sensitive and hypermutable to BP-G suggests that these properties are also employed by Pol κ to bypass across BP-G adducts *in vivo* (Ogi et al., 2002). The sensitivity of Pol κ deficient cells to UV radiation (Schenten et al., 2002;Ziv et al., 2009), is more difficult to understand as *in vitro* the enzyme does not support TLS across CPD or [6-4] photoproducts (the other main type of UV induced DNA damage). There are however indications, that Pol κ might function in extending from bypassed UV lesions (Washington et al., 2002) and removal of UV lesions by Nucleotide Excision Repair (Ogi et al., 2010;Ogi and Lehmann, 2006). Pol κ seems not essential for somatic hypermutation in Pol κ deficient mice (Schenten et al., 2002; Shimizu et al., 2003). However, the residual A/T mutations found in Pol η deficient B cells have been demonstrated to depend on Pol κ and at least a third yet unidentified polymerase (Faili et al., 2009). This

observation is compatible with the error-signature of Polk *in vitro* (Ohashi et al., 2000). Apparently, Polk can substitute Pol η whereas other polymerases of the Y-family, for example Rev1, cannot, as revealed by the normal generation of G to C transversions in Pol η deficient mice (see below).

Rev1

Rev1 is selective in its nucleotide incorporation activity as it only incorporates dCMP and therefore in its strictest sense should be regarded as a deoxycytidyl transferase rather than a bona fide DNA polymerase. *In vitro*, Rev1 is able to efficiently and specifically insert dCMP opposite an AP site or a uracil residue, but not opposite a CPD or a [6–4] photoproduct (Nelson et al., 1996; Masuda et al., 2002; Masuda et al., 2001; Lin et al., 1999). The sensitivity of Rev1 mutant cells to UV radiation (Simpson and Sale, 2003; Jansen et al., 2009; Jansen et al., 2006) has therefore been linked to a structural role of Rev1 (Nelson et al., 2000; Ross et al., 2005; Masuda et al., 2009). As the C-terminal region of REV1 can interact with Pol η , Pol ι , Polk and the noncatalytic REV7 subunit of Polz (Murakumo et al., 2001; Ohashi et al., 2004; Guo et al., 2003), Rev1 have been proposed to direct TLS polymerases for bypass of UV lesions, which would explain the important role of Rev1 in DNA damage-induced mutagenesis (Lawrence, 2002; Jansen et al., 2006; Jansen et al., 2009; Friedberg, 2005). Consistently, the Rev1 C-terminal interaction region is required for resistance to DNA-damaging agents in chicken DT40 cells (Ross et al., 2005). In addition to the C-terminal interaction region Rev1 harbors a BRCA1 C-terminal (BRCT) domain in its N-terminus (Gerlach et al. 1999). This domain is required for (mutagenic) TLS and resistance to UV irradiation and other DNA-damaging agents (Lawrence, 2002; Jansen et al., 2005). BRCT domains have been identified in many cell cycle and DNA repair proteins (Huyton et al., 2000), and are thought to mediate protein interactions by binding to proteins that are phosphorylated by the DNA damage-activated protein kinases ATR and ATM (Yu et al., 2003). It has been shown that Rev1 could bind PCNA via this domain, (Guo et al., 2006a; Jansen et al., 2007). Future studies should reveal whether other proteins, like for example the 9-1-1 complex (see below) are bound by the BRCT domain of Rev1 (Jansen et al., 2007).

B cells derived from Rev1 deficient and catalytic mutant mice as well as chicken DT40 cells indicated a role for the catalytic activity of Rev1 in SHM (Jansen et al., 2006; Ross and Sale, 2006; Masuda et al., 2009; Arakawa et al., 2006). In agreement with the reported *in vitro* ability of Rev1 to bypass AP sites lesion (Nelson et al., 1996), C to G and G to C transversions are reduced in Rev1 mutant B cells. While in chicken DT40 B cells Rev1 is required for the generation of most of the C to G and G to C transversions, Rev1 seems to generate only part of these mutations in mammalian B cells, indicating that other polymerases can make these transversions in the absence of Rev1. While the BRCT domain of Rev1 was shown to regulate TLS of AP sites in yeast (Haracska et al. 2001), the BRCT domain is dispensable during SHM (Jansen et al. 2005). Furthermore, as

A/T mutations are still present in Rev1 deficient B cells (Jansen et al., 2006), the C-terminal polymerase binding region of Rev1 is dispensable for most Pol η and Pol κ activity during SHM.

Pol ι

Observations that 'knock-down' of Pol ι greatly increases the sensitivity of cells to oxidizing agents (Petta et al., 2008), that Pol ι displays BER activity *in vitro* and *in vivo* (Petta et al., 2008;Bebenek et al., 2001) and accurately bypasses 8-oxo-G (12), have implicated Pol ι in the protection against oxidative stress. In addition, *in vitro* and *in vivo* studies have indicated a role for Pol ι in bypassing both CPD and (6-4) PP (Tissier et al., 2000;Ziv et al., 2009;Yoon et al., 2010;Johnson et al., 2000). Pol ι deficiency does not result in a survival disadvantage after UV radiation in Pol η proficient cells, however it does result in higher sensitivity and hypomutability to UV in the absence of Pol η in some (Gueranger et al., 2008;Dumstorf et al., 2006;Ziv et al., 2009), but not all (Ohkumo et al., 2006;Ziv et al., 2009) studies. Moreover, the absence of Pol ι increased the onset of UV-induced skin cancers in Pol η deficient mice (Dumstorf et al., 2006;Ohkumo et al., 2006). So while Pol ι may protect against UV radiation *in vivo*, the mutagenic bypass of these lesions by Pol ι and other polymerases may result in cancer as seen in XP-V patients. Given the extreme low-fidelity of Pol ι when copying undamaged DNA, Pol ι has been proposed as a candidate TLS polymerase in SHM. *In vitro* Pol ι prefers to insert a G rather than an A opposite of T (Zhang et al. 2000)(Johnson et al., 2000;Tissier et al., 2000). In addition Pol ι has a preference to insert either G or T residues opposite of AP sites (Zhang et al. 2001). While incorporation of G opposite of an AP site will faithfully restore the initial AID induced lesion, the introduction of a T will result in C to A and G to T transversions. Actually, the TLS polymerase(s) involved in establishing these transversions during SHM remain to be identified. No changes in SHM were observed in B cells derived from a 129/J-mouse strain that carries a spontaneous nonsense mutation in the Pol ι gene (McDonald et al. 2003). Western blot analysis on testis extracts indeed showed the absence of Pol ι in this strain. Nevertheless, it has been described that there may be tissue specific and functional alternative splice forms of Pol ι , and 'Pol ι activity' seems to be retained in brain extract from this mouse strain (Gening et al. 2006). In this context, 129/J-derived B cells should be tested for the presence of hypomorph versions of Pol ι . At present, one cannot formally exclude that Pol ι is involved in SHM. Analysis of B cells derived from mouse mutants carrying a targeted deletion of Pol ι will solve this issue.

Pol ζ

Pol ζ is a heterodimer composed of a catalytic Rev3 and structural Rev7 protein that extends efficiently from mispaired primer termini on undamaged DNA (Gan et al., 2008), and is the only polymerase whose deficiency in mammals is embryonic lethal (Bemark et al., 2000;Kajiwarra et al., 2001;Kawamura et al.,

2001;Van Sloun et al., 2002;Wang et al., 2002). Rev3 deficient chicken DT40 B cells revealed a central role of Rev3 in maintaining genome stability. Beside a defect in TLS, these cells showed reduced gene targeting efficiencies and a significant increase in the level of genomic breaks after ionizing radiation (Sonoda et al., 2003). In mammals Rev3 has been suggested to be essential for the bypass of 6-4 PP during the repair of post replicative gaps, while mostly dispensable for the bypass of CPDs. (Jansen et al 2009). These observations are consistent with results obtained from a plasmid gap assay, in which TLS across 6-4PP strongly depends on Rev3, but not across CPDs (Shachar et al., 2009). Interestingly, TLS across AP site was only 2 fold reduced in Rev3 deficient cells in this assay. While together with Rev1, Pol ζ is responsible for the majority of DNA damage-induced and spontaneous mutations in yeast and mammals (Lemontt, 1971;Gan et al., 2008) it is currently unknown whether Pol ζ is involved in SHM. A 'knock down' of the catalytic subunit Rev3 in human B cells or in transgenic mice revealed a decrease in the frequency of somatic hypermutation (Diaz et al., 2001; Zan et al., 2001). Consistently, *in vivo* gene ablation of Rev3 in mature B cells reduced the frequency of somatic mutations (Schenten et al., 2009). As the pattern of SHM was unaffected, these results could imply that Pol ζ during SHM is involved in all mutations. However as at least G/C transitions do not completely depend on Pol ζ , the observed phenotype is at least partly caused by the enormous sensitivity of cells to Rev3 ablation.

Other TLS polymerases: Pol λ , Pol μ , Pol θ and Pol ν

In addition to the above mentioned polymerases, Pol λ , Pol μ , Pol θ and Pol ν have shown translesion activity *in vitro*. While Pol λ and Pol μ appear dispensable for SHM (Bertocci et al., 2002) (Lucas et al., 2005), a role for Pol θ was initially proposed by the labs of Casali and O-Wang. *In vitro* Pol θ is capable of direct catalytic bypass of abasic sites, strongly favoring dAMP (Seki et al., 2004). While the lab of Casali reported a dramatic decrease in the frequency of mutations and an increase in G/C transitions, the lab of O-Wang reported that Pol θ deficient mice had only a mild reduction in the number of mutations and an increase in G to C transversions. In addition, the O-Wang group analyzed SHM in mice expressing a catalytically inactive Pol θ and found an actual decrease in mutations at template G/C. Given these striking differences, the Gearhart group recently reexamined this issue in Pol θ deficient mice and Pol θ /Pol η double deficient mice. Based on the frequency and spectra of the mutations they observed, Pol θ has no major role in somatic hypermutation (Martomo et al., 2008;Masuda et al., 2006;Zan et al., 2005;Masuda et al., 2005). The only non-replicative polymerases not tested for its role in SHM is Pol ν due to the lack of a Pol ν deficient mouse model (Marini et al., 2003). *In vitro* the vast majority of errors made by Pol ν reflect misincorporation of dTMP opposite template G, while its error signature across AP site is currently unknown.

In summary, only Pol η and Rev1 appear to have non-redundant functions in establishing most A/T mutations and G to C transversions, respectively. Other TLS polymerases are likely involved and might compensate the absence of others. The diversity of structurally related TLS polymerases raises a central question: What regulates the activation of TLS polymerases during SHM?

REGULATING TLS BY PCNA UBIQUITINATION

Non-instructive DNA lesions cause problems for high fidelity polymerases and lead to replication fork stalling. If the “stalling” lesion is not repaired, the replication fork may collapse (Tercero & Diffley 2001). Such a collapse can generate double strand breaks, which can in turn trigger cell death (McGlynn & Lloyd 2002). To maintain genomic integrity and prevent the generation of death signals by secondary lesions, eukaryotic cells are equipped with DNA damage tolerance (DDT) pathways to continue replication without an *a priori* repair of the initial lesion (Friedberg, 2005). Cells are equipped with two alternative DNA damage tolerance pathways: TLS (damage bypass) and homology-dependent damage avoidance (HDA; all mechanisms that rely on a homologous donor; this includes strand transfer from the donor (homologous recombination), and template switching, in which the information is copied from the donor) (Friedberg 2005; Haracska et al. 2001; Lawrence 1994; Murli & Walker 1993). HDA uses intact DNA of the sister chromatid or the homologous chromosome to continue replication and is therefore mainly error free (Zhang & Lawrence 2005). As mentioned previously,




Figure 3. PCNA modification and functions in *S. cerevisiae*. In the absence of DNA damage, *S. cerevisiae* PCNA is SUMOylated at K164 or K127 (not depicted), which inhibits homologous recombination during replication by recruiting Srs2. Upon fork stalling PCNA is monoubiquitinated at K164 by Rad6/Rad18 to activate direct translesion synthesis across the stalling lesion. Alternatively PCNA can be further polyubiquitinated by Ubc13/Mms2/Rad5 to stimulate template switching.



TLS enables direct replication across the damaged template and depending on the type of damage and the TLS polymerase involved, can be highly error prone.

Studies in *S. cerevisiae* identified that both modes of lesion bypass appear to be controlled by specific posttranslational modifications of the homotrimeric DNA sliding clamp PCNA (Fig.3). PCNA is an essential binding platform for numerous proteins involved in DNA replication, repair, and cell cycle regulation. PCNA tethers DNA polymerases to their substrate and thereby serves as a critical processivity factor for DNA synthesis (Moldovan et al., 2007). During replication, the replicative polymerases bind PCNA through its PIP (PCNA-interacting peptide) box (Warbrick 1998). When the high fidelity replication machinery is stalled upon encountering a lesion, PCNA becomes monoubiquitinated (PCNA-Ub) at lysine residue 164 (PCNA^{K164}) by the ubiquitin-conjugating/ligating complex Rad6/Rad18 (E2/E3) (Hoeye et al. 2002). In addition, the heterodimeric E2 ubiquitin conjugase consisting of Ubc13 and Mms2 cooperates with the RING finger E3 ligase Rad5 in specific lysine 63-linked polyubiquitination of PCNA-Ub (PCNA-Ubⁿ). Besides ubiquitination, modification of PCNA by the small ubiquitin-like modifier SUMO occurs by Ubc9 and Siz1 at K164 and K127 in *S. cerevisiae* (Hoeye et al., 2002). As deletion of Pol η , Rev1 and Pol ζ does further sensitize Rad5- and Siz1-deficient strains, but not Rad6 and PCNA^{K164R} mutant strains to UV radiation (Stelter and Ulrich, 2003; Lawrence and Christensen, 1976; McDonald et al., 1997; Hoeye et al., 2002), it is now generally accepted that in *S. cerevisiae* PCNA-Ub is essential for activation of TLS-dependent damage tolerance, while PCNA-Ubⁿ activates HDA. In agreement, PCNA-Ub is a prerequisite for Pol ζ - and Rev1-dependent, damage-induced mutagenesis (Lawrence and Christensen, 1976; Stelter and Ulrich, 2003), while PCNA-Ubⁿ deficient strains show an increased TLS-mediated spontaneous and damage-induced mutagenesis (Broomfield et al., 1998; Brusky et al., 2000; Johnson et al., 1992). PCNA-SUMO is most prominent during S phase and unlike ubiquitination is not markedly enhanced in the presence of DNA-damaging agents. It has been suggested that PCNA-SUMO recruits Srs2 to the replication fork, a helicase that inhibits homologous recombination (Pfander et al., 2005; Papouli et al., 2005; Haracska et al., 2004), and hereby regulates the Rad5 mediated error-free pathway (Branzei et al., 2008) and prevents unwanted recombination during replication stalling. However, in the absence of RAD6 dependent DDT the suppression of homologous recombination makes yeast even more sensitive to replication-stalling agents and replication error-prone due to an increased contribution of Pol ζ . Thus in contrast to damage-induced mutagenesis, both mono-ubiquitin and SUMO conjugation to PCNA can contribute to the activation of Pol ζ for spontaneous mutagenesis (Hastings et al., 1976; Stelter and Ulrich, 2003; Quah et al., 1980), although PCNA-SUMO most likely in an independent manner.

PCNA MODIFICATION IN HIGHER EUKARYOTES

Like in *S. cerevisiae*, UV-irradiation in higher eukaryotes lead to PCNA-Ub at the conserved K164 residue (Kannouche et al. 2004). As mammalian cells and chicken DT40 cells impaired for PCNA ubiquitination are sensitive to replication fork blocking lesions (Watanabe et al., 2004; Arakawa et al., 2006; Niimi et al., 2008), it has been suggested that, like in yeast, TLS in higher eukaryotes strongly depends on PCNA-Ub. In agreement, PCNA-Ub in mammals increases its affinity for Pol η , Pol ι and Rev1 (Watanabe et al., 2004; Kannouche et al., 2004; Bienko et al., 2005; Plosky et al., 2006; Guo et al., 2006b), which is believed to depend on the Ub-binding domain (UBD) of TLS polymerases (Bienko et al., 2005). In line with these observations, the recruitment of TLS polymerases to sites of UV damage is impaired in cells lacking Rad18 or when the UBDs are mutated (Watanabe et al., 2004; Bienko et al., 2005; Guo et al., 2008; Guo et al., 2006b; Plosky et al., 2006). In contrast, Rev1 was observed to act mainly independently of PCNA-Ub in chicken DT40 cells to recover from UV induced replication blocks (Edmunds et al., 2008), while the dependence of Rev1 on PCNA-Ub in mammals is currently unknown. Furthermore, the involvement of PCNA-Ub and the UBD in regulating Pol η in mammals has recently been questioned. The bypass of a CPD lesion was shown to be as efficient in cell extracts of Rad18-deficient cells as in wild-type (WT) cell extracts (Schmutz et al., 2010). Furthermore, Lehmann, *et al.* suggested that PCNA-Ub is not required for Pol η accumulation into foci, but only increases the residence time of Pol η within foci (Sabbioneda et al., 2008) and proposed a model in which the UBD domain is targeted to an unknown protein, which results in loading of Pol η to PCNA-Ub (Gohler et al., 2011). In contrast, Prakash, *et al.* indicated that not all conserved residues in the UBD domain effect Pol η function, suggesting that Ub binding by the UBD of Pol η is dispensable for its activation (Acharya et al., 2008; Acharya et al., 2010).

POLYUBIQUITINATION OF PCNA IN HIGHER EUKARYOTES

Like in yeast, damage-inducible PCNA-Ubⁿ has been observed, although to a lesser extent, in mammals (Chiu et al., 2006), and was found to be mediated by two Rad5 orthologs, HLF and SHPRH. Like Rad5, both SHPRH and HLF physically interact with the RAD6/RAD18 and UBC13/MMS2 complexes and promote PCNA polyubiquitination at K164 in a RAD18-dependent manner (Motegi et al., 2006; Motegi et al., 2008; Unk et al., 2006; Unk et al., 2008). The role for PCNA-Ubⁿ in mammals is currently unknown, however depletion of either SHPRH or HLF in human cells increases the sensitivity to methyl methanesulfonate (MMS) and enhances genomic instability. These data implicate a role for PCNA-Ubⁿ in



mammalian DNA damage tolerance. Furthermore, in human fibroblasts the reduced expression of MMS2 and the inhibition of K63 polyubiquitination have been shown to increase the frequency of UV-induced mutations (Li et al., 2002; Chiu et al., 2006), suggesting that like in yeast PCNA-Ubⁿ prevents TLS-mediated mutagenesis.

SUMOYLATION OF PCNA IN HIGHER EUKARYOTES

While the minor SUMO conjugation site of PCNA^{K127} is not conserved in higher eukaryotes, SUMOylation of PCNA has been detected at K164 in chicken DT40 cells (Arakawa et al., 2006). It is currently unknown what the consequences of this modification are in DT40 cells and whether PCNA-SUMO occurs in mammals. Furthermore, no homologs of Srs2 have been identified in higher eukaryotes, although other helicases have been identified that could substitute Srs2 by inhibiting HR in mammalian cells (Marini and Krejci, 2010).

SHM AT TEMPLATE A/T REQUIRES PCNA MODIFICATION IN MAMMALS

To determine whether PCNA modification regulates the generation of somatic mutations in hypermutating B cells, PCNA mutant mice that contain a lysine 164 to arginine mutation (PCNA^{K164R}) have been analyzed for SHM. Analysis of the mutation spectrum of Ig genes in B cells from these knock-in mice revealed a ten-fold reduction in A/T mutations (Langerak et al., 2007). In agreement, PCNA knock-out mice reconstituted with a PCNA^{K164R} transgene showed a reduction of A/T mutations in Ig genes (Roa et al., 2008). These data suggest that most A/T mutations are regulated by PCNA-Ub. As A/T mutations depend mainly on polymerase η (and in its absence polymerase κ and at least a third yet unidentified polymerase (Faili et al., 2009), these data suggest that during MSH2-dependent SHM, and possibly during Ung2-dependent SHM, both Pol η and Pol κ depend on PCNA-Ub to establish most A/T mutations. Interestingly, it has been suggested that PCNA-Ubⁿ in B cells suppresses mutagenesis during SHM, similar to PCNA-Ubⁿ in yeast during spontaneous and damage-induced mutagenesis (Motegi et al., 2008). However, as this study was performed in a B cell line in which only a minority of the mutations are known to be at template A/T and the mutation spectrum in this study was not determined, the underlying mechanism is currently unclear.

PCNA-UB INDEPENDENT G/C TRANSVERSIONS DURING SHM

While most A/T mutations depend on PCNA-Ub, the generation of G/C transversions is not impaired in PCNA^{K164R} mutant B cells. Given the role for the TLS polymerase Rev1 in generating G to C transversions during SHM (Jansen et al., 2006; Ross and Sale, 2006), these findings exclude a role of PCNA-Ub in activating Rev1 and all other yet unidentified 'G/C transverters' during SHM in mammals. In agreement, damage tolerance mediated by Rev1 was found to be independent of PCNA-Ub in the chicken DT40 B cell line (Edmunds et al., 2008). In contrast, in DT40 cells, Rev1 depends on PCNA-Ub to generate G to C transversions during SHM (Arakawa et al., 2006). How G to C transversions are controlled during SHM in mammals is currently unknown, however as both the Rad9-Rad1-Hus1 complex (9-1-1) and the Fanconi Anemia pathway have been reported to regulate TLS, analysis of these pathways may reveal the answer to this question.

REGULATING TLS BY 9-1-1

The heterotrimeric 9-1-1 complex is structurally very similar to PCNA (Dore et al., 2009) and is loaded by Rad17 onto DNA in response to replication fork stalling where it triggers the activation of the cell cycle checkpoint and possibly DNA repair in both yeast and higher eukaryotes (Bermudez et al., 2003; Volkmer and Karnitz, 1999; Bai et al., 2010; Parrilla-Castellar et al., 2004). Interestingly, in yeast the 9-1-1 complex is also required for DNA damage-induced mutagenesis, possibly by its direct interaction with Pol κ and Pol ζ (Kai and Wang, 2003; Sabbioneda et al., 2005). Whether the 9-1-1 complex regulates TLS during DDT and SHM in mammals is currently unknown. Deficiency of Rad17, or any member of the 9-1-1 complex is embryonic lethal in mice, and results in cell death in mouse embryonic fibroblast (Hopkins et al., 2004; Weiss et al., 2000; Budzowska et al., 2004). In contrast, mouse embryonic stem cells deficient for Rad9, chicken DT40 B cells deficient for Rad9 or Rad17 and Hus1 mouse embryonic fibroblasts deficient for p21 can be grown in culture, although these cell lines are hypersensitive to UV, MMS and HU (Weiss et al., 2000; Hopkins et al., 2004; Kobayashi et al., 2004). These observations indicate that in higher eukaryotes the 9-1-1 complex is not required for cell survival *per se*, but is essential under replication stalling conditions.

REGULATING TLS BY THE FA PATHWAY

Fanconi anemia (FA) is an autosomal recessive genetic disorder, which at the cellular level is characterized by a hypersensitivity to DNA cross-linking agents such as cisplatin (Kee and D'Andrea, 2010). How the FA pathway mediates

resistance to cross-links is largely unknown. Current models suggest that after replicative DNA polymerases are stalled at a DNA cross-link, FANCD2 and FANCI become monoubiquitinated by the FA core complex. The FA core complex consists of eight essential FA proteins, FANCA, -B, -C, -E, -F, -G, -L, -M, and two FA-Associated Proteins FAAP100 and FAAP24. FANCD2 was shown to stimulate incision of one of the strands containing the cross-link and to recruit TLS polymerases to enable a direct replicative bypass (Knipscheer et al., 2009). In agreement, the TLS polymerases Rev1 and Rev3 have been demonstrated to act synergistically with the FA pathway in cross-link repair in chicken DT40 B cells (Niedzwiedz et al., 2004). Interestingly, it has been reported that chicken DT40 B cells deficient for members of the FA pathway show a decrease in SHM (Yamamoto et al., 2005; Niedzwiedz et al., 2004). Although the precise mechanism for the decrease in the accumulation of non-templated mutations is currently unclear, it is intriguing to speculate that the FA pathway may regulate TLS polymerases like Rev1 during SHM to generate these mutations.

SCOPE OF THIS THESIS

This thesis focuses on the regulation of TLS polymerases during DDT and especially its mutagenic function during SHM of immunoglobulin genes. While the first part (chapters 2 –6) of this thesis addresses the role of specific post-translational modifications of lysine residue 164 in PCNA (PCNA^{K164}) in controlling SHM, DDT, and meiosis, the second part (chapter 7-9) addresses PCNA^{K164} independent, regulatory aspects of SHM and DDT. In chapter 2, we first determined where in the previously described SHM pathways (Fig 2) PCNA^{K164} dependent mutations are located and what the contributions of Msh2 and Ung2 are (Chapter 2). We next investigated whether the two known mammalian homologs of Rad5, SHPRH and HLF, responsible for polyubiquitination of PCNA regulate mutagenesis during SHM, and whether they are essential for survival upon DNA damaging agents in mammals (Chapter 3). In Chapter 4 and 5, we investigated the role of PCNA modification in mammalian DDT. Specifically we questioned whether PCNA modification is essential for polymerase η function upon UV damage, and TLS in general across specific lesions. In addition we determined the role of PCNA modification in regulating polymerase η during SHM. In Chapter 6, we examined why PCNA^{K164R} mutant mice display severe defects in germ cell development by analyzing the function and nature of the PCNA modification in spermatogenesis in more detail. In the last chapters we study the contribution of the Msh2 pathway (Chapter 7), the Fanconi Anemia pathway (Chapter 8) and the proposed topological counterpart of PCNA^{K164} in the 9-1-1 complex (Chapter 9) during SHM. Finally, a general discussion of the preceding chapters and their relation to published literature is presented in Chapter 10.

REFERENCES

1. Acharya, N. , J. H. Yoon, H. Gali, I. Unk, L. Haracska, R. E. Johnson, J. Hurwitz, L. Prakash, and S. Prakash. 2008. Roles of PCNA-binding and ubiquitin-binding domains in human DNA polymerase eta in translesion DNA synthesis. *Proc. Natl. Acad. Sci. U. S. A* 105:17724-17729.
2. Acharya, N. , J. H. Yoon, J. Hurwitz, L. Prakash, and S. Prakash. 2010. DNA polymerase eta lacking the ubiquitin-binding domain promotes replicative lesion bypass in humans cells. *Proc. Natl. Acad. Sci. U. S. A* 107:10401-10405.
3. Arakawa, H. , G. L. Moldovan, H. Saribasak, N. N. Saribasak, S. Jentsch, and J. M. Buerstedde. 2006. A role for PCNA ubiquitination in immunoglobulin hypermutation. *PLoS. Biol.* 4:e366.
4. Bai, H. , A. Madabushi, X. Guan, and A. L. Lu. 2010. Interaction between human mismatch repair recognition proteins and checkpoint sensor Rad9-Rad1-Hus1. *DNA Repair (Amst)* 9:478-487.
5. Bardwell, P. D. , A. Martin, E. Wong, Z. Li, W. Edelmann, and M. D. Scharff. 2003. Cutting edge: the G-U mismatch glycosylase methyl-CpG binding domain 4 is dispensable for somatic hypermutation and class switch recombination. *J. Immunol.* 170:1620-1624.
6. Bardwell, P. D. , C. J. Woo, K. Wei, Z. Li, A. Martin, S. Z. Sack, T. Parris, W. Edelmann, and M. D. Scharff. 2004. Altered somatic hypermutation and reduced class-switch recombination in exonuclease 1-mutant mice. *Nat. Immunol.* 5:224-229.
7. Beale, R. C. , S. K. Petersen-Mahrt, I. N. Watt, R. S. Harris, C. Rada, and M. S. Neuberger. 2004. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. *J. Mol. Biol.* 337:585-596.
8. Bebenek, K. , A. Tissier, E. G. Frank, J. P. McDonald, R. Prasad, S. H. Wilson, R. Woodgate, and T. A. Kunkel. 2001. 5'-Deoxyribose phosphate lyase activity of human DNA polymerase iota in vitro. *Science* 291:2156-2159.
9. Bemark, M. , A. A. Khamlichi, S. L. Davies, and M. S. Neuberger. 2000. Disruption of mouse polymerase zeta (Rev3) leads to embryonic lethality and impairs blastocyst development in vitro. *Curr. Biol.* 10:1213-1216.
10. Bermudez, V. P. , L. A. Lindsey-Boltz, A. J. Cesare, Y. Maniwa, J. D. Griffith, J. Hurwitz, and A. Sancar. 2003. Loading of the human 9-1-1 checkpoint complex onto DNA by the checkpoint clamp loader hRad17-replication factor C complex in vitro. *Proc. Natl. Acad. Sci. U. S. A* 100:1633-1638.
11. Bertocci, B. , S. A. De, E. Flatter, A. Dahan, J. C. Bories, C. Landreau, J. C. Weill, and C. A. Reynaud. 2002. Cutting edge: DNA polymerases mu and lambda are dispensable for Ig gene hypermutation. *J. Immunol.* 168:3702-3706.
12. Bienko, M. , C. M. Green, N. Crosetto, F. Rudolf, G. Zapart, B. Coull, P. Kannoche, G. Wider, M. Peter, A. R. Lehmann, K. Hofmann, and I. Dikic. 2005. Ubiquitin-binding domains in Y-family polymerases regulate translesion synthesis. *Science* 310:1821-1824.
13. Branzei, D. , F. Vanoli, and M. Foiani. 2008. SUMOylation regulates Rad18-mediated template switch. *Nature* 456:915-920.
14. Brenner, S. and C. Milstein. 1966. Origin of antibody variation. *Nature* 211:242-243.
15. Broomfield, S. , B. L. Chow, and W. Xiao. 1998. MMS2, encoding a ubiquitin-conjugating-enzyme-like protein, is a member of the yeast error-free postreplication repair pathway. *Proc. Natl. Acad. Sci. U. S. A* 95:5678-5683.
16. Brusky, J. , Y. Zhu, and W. Xiao. 2000. UBC13, a DNA-damage-inducible gene, is a member of the error-free postreplication repair pathway in *Saccharomyces cerevisiae*. *Curr. Genet.* 37:168-174.
17. Budzowska, M. , I. Jaspers, J. Essers, W. H. de, D. E. van, K. Hanada,

- B. Beverloo, R. W. Hendriks, K. A. de, R. Kanaar, J. H. Hoeijmakers, and A. Maas. 2004. Mutation of the mouse Rad17 gene leads to embryonic lethality and reveals a role in DNA damage-dependent recombination. *EMBO J.* 23:3548-3558.
18. Chaudhuri, J. , M. Tian, C. Khuong, K. Chua, E. Pinaud, and F. W. Alt. 2003. Transcription-targeted DNA deamination by the AID antibody diversification enzyme. *Nature* 422:726-730.
19. Chiu, R. K. , J. Brun, C. Ramaekers, J. Theys, L. Weng, P. Lambin, D. A. Gray, and B. G. Wouters. 2006. Lysine 63-polyubiquitination guards against translesion synthesis-induced mutations. *PLoS. Genet.* 2:e116.
20. Delbos, F. , S. Aoufouchi, A. Faili, J. C. Weill, and C. A. Reynaud. 2007. DNA polymerase eta is the sole contributor of A/T modifications during immunoglobulin gene hypermutation in the mouse. *J. Exp. Med.* 204:17-23.
21. Delbos, F. , S. A. De, A. Faili, S. Aoufouchi, J. C. Weill, and C. A. Reynaud. 2005. Contribution of DNA polymerase eta to immunoglobulin gene hypermutation in the mouse. *J. Exp. Med.* 201:1191-1196.
22. Di Noia, J. M. and M. S. Neuberger. 2007. Molecular mechanisms of antibody somatic hypermutation. *Annu. Rev. Biochem.* 76:1-22.
23. Di Noia, J. M. , C. Rada, and M. S. Neuberger. 2006. SMUG1 is able to excise uracil from immunoglobulin genes: insight into mutation versus repair. *EMBO J.* 25:585-595.
24. Dickerson, S. K. , E. Market, E. Besmer, and F. N. Papavasiliou. 2003. AID mediates hypermutation by deaminating single stranded DNA. *J. Exp. Med.* 197:1291-1296.
25. Dore, A. S. , M. L. Kilkenny, N. J. Rzechorzek, and L. H. Pearl. 2009. Crystal structure of the rad9-rad1-hus1 DNA damage checkpoint complex--implications for clamp loading and regulation. *Mol. Cell* 34:735-745.
26. Dorner, T. , S. J. Foster, N. L. Farner, and P. E. Lipsky. 1998. Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. *Eur. J. Immunol.* 28:3384-3396.
27. Dumstorf, C. A. , A. B. Clark, Q. Lin, G. E. Kissling, T. Yuan, R. Kucherlapati, W. G. McGregor, and T. A. Kunkel. 2006. Participation of mouse DNA polymerase iota in strand-biased mutagenic bypass of UV photoproducts and suppression of skin cancer. *Proc. Natl. Acad. Sci. U. S. A* 103:18083-18088.
28. Edmunds, C. E. , L. J. Simpson, and J. E. Sale. 2008. PCNA ubiquitination and REV1 define temporally distinct mechanisms for controlling translesion synthesis in the avian cell line DT40. *Mol. Cell* 30:519-529.
29. Ehrenstein, M. R. , C. Rada, A. M. Jones, C. Milstein, and M. S. Neuberger. 2001. Switch junction sequences in PMS2-deficient mice reveal a microhomology-mediated mechanism of Ig class switch recombination. *Proc. Natl. Acad. Sci. U. S. A* 98:14553-14558.
30. Esposito, G. , G. Texido, U. A. Betz, H. Gu, W. Muller, U. Klein, and K. Rajewsky. 2000. Mice reconstituted with DNA polymerase beta-deficient fetal liver cells are able to mount a T cell-dependent immune response and mutate their Ig genes normally. *Proc. Natl. Acad. Sci. U. S. A* 97:1166-1171.
31. Faili, A. , A. Stary, F. Delbos, S. Weller, S. Aoufouchi, A. Sarasin, J. C. Weill, and C. A. Reynaud. 2009. A backup role of DNA polymerase kappa in Ig gene hypermutation only takes place in the complete absence of DNA polymerase eta. *J. Immunol.* 182:6353-6359.
32. Frey, S. , B. Bertocci, F. Delbos, L. Quint, J. C. Weill, and C. A. Reynaud. 1998. Mismatch repair deficiency interferes with the accumulation of mutations in chronically stimulated B cells and not with the hypermutation process. *Immunity.* 9:127-134.
33. Friedberg, E. C. 2005. Suffering in silence: the tolerance of DNA damage. *Nat. Rev. Mol. Cell Biol.* 6:943-953.
34. Friedberg, E. C. , G. C. walker, W. Siede, R. D. Wood, R. A. Schulz, and

- T. Ellenberger. 2006. DNA repair and Mutagenesis. ASM Press.
35. Gan, G. N. , J. P. Wittschleben, B. O. Wittschleben, and R. D. Wood. 2008. DNA polymerase zeta (pol zeta) in higher eukaryotes. *Cell Res.* 18:174-183.
 36. Gohler, T. , S. Sabbioneda, C. M. Green, and A. R. Lehmann. 2011. ATR-mediated phosphorylation of DNA polymerase eta is needed for efficient recovery from UV damage. *J. Cell Biol.* 192:219-227.
 37. Gueranger, Q. , A. Stary, S. Aoufouchi, A. Faili, A. Sarasin, C. A. Reynaud, and J. C. Weill. 2008. Role of DNA polymerases eta, iota and zeta in UV resistance and UV-induced mutagenesis in a human cell line. *DNA Repair (Amst)* 7:1551-1562.
 38. Guo, C. , P. L. Fischhaber, M. J. Luk-Paszyc, Y. Masuda, J. Zhou, K. Kamiya, C. Kisker, and E. C. Friedberg. 2003. Mouse Rev1 protein interacts with multiple DNA polymerases involved in translesion DNA synthesis. *EMBO J* 22:6621-6630.
 39. Guo, C. , J. N. Kosarek-Stancel, T. S. Tang, and E. C. Friedberg. 2009. Y-family DNA polymerases in mammalian cells. *Cell Mol. Life Sci.* 66:2363-2381.
 40. Guo, C. , E. Sonoda, T. S. Tang, J. L. Parker, A. B. Bielen, S. Takeda, H. D. Ulrich, and E. C. Friedberg. 2006a. REV1 protein interacts with PCNA: significance of the REV1 BRCT domain in vitro and in vivo. *Mol. Cell* 23:265-271.
 41. Guo, C. , T. S. Tang, M. Bienko, I. Dikic, and E. C. Friedberg. 2008. Requirements for the interaction of mouse Polkappa with ubiquitin and its biological significance. *J Biol Chem* 283:4658-4664.
 42. Guo, C. , T. S. Tang, M. Bienko, J. L. Parker, A. B. Bielen, E. Sonoda, S. Takeda, H. D. Ulrich, I. Dikic, and E. C. Friedberg. 2006b. Ubiquitin-binding motifs in REV1 protein are required for its role in the tolerance of DNA damage. *Mol Cell Biol* 26:8892-8900.
 43. Haracska, L. , C. A. Torres-Ramos, R. E. Johnson, S. Prakash, and L. Prakash. 2004. Opposing effects of ubiquitin conjugation and SUMO modification of PCNA on replicational bypass of DNA lesions in *Saccharomyces cerevisiae*. *Mol. Cell Biol.* 24:4267-4274.
 44. Haracska, L. , S. L. Yu, R. E. Johnson, L. Prakash, and S. Prakash. 2000. Efficient and accurate replication in the presence of 7,8-dihydro-8-oxoguanine by DNA polymerase eta. *Nat. Genet.* 25:458-461.
 45. Hastings, P. J. , S. K. Quah, and R. C. von Borstel. 1976. Spontaneous mutation by mutagenic repair of spontaneous lesions in DNA. *Nature* 264:719-722.
 46. Hoege, C. , B. Pfander, G. L. Moldovan, G. Pyrowolakis, and S. Jentsch. 2002. RAD6-dependent DNA repair is linked to modification of PCNA by ubiquitin and SUMO. *Nature* 419:135-141.
 47. Hopkins, K. M. , W. Auerbach, X. Y. Wang, M. P. Hande, H. Hang, D. J. Wolgemuth, A. L. Joyner, and H. B. Lieberman. 2004. Deletion of mouse rad9 causes abnormal cellular responses to DNA damage, genomic instability, and embryonic lethality. *Mol. Cell Biol.* 24:7235-7248.
 48. Huyton, T. , P. A. Bates, X. Zhang, M. J. Sternberg, and P. S. Freemont. 2000. The BRCA1 C-terminal domain: structure and function. *Mutat. Res.* 460:319-332.
 49. Jacobs, H. , Y. Fukita, G. T. van der Horst, B. J. de, G. Weeda, J. Essers, W. N. de, B. P. Engelward, L. Samson, S. Verbeek, J. M. de Murcia, M. G. de, R. H. te, and K. Rajewsky. 1998. Hypermutation of immunoglobulin genes in memory B cells of DNA repair-deficient mice. *J. Exp. Med.* 187:1735-1743.
 50. Jansen, J. G. , M. I. Fousteri, and W. N. de. 2007. Send in the clamps: control of DNA translesion synthesis in eukaryotes. *Mol. Cell* 28:522-529.
 51. Jansen, J. G. , P. Langerak, A. Tsaalbi-Shtylik, B. P. van den, H. Jacobs, and W. N. de. 2006. Strand-biased defect in C/G transversions in hypermutating

- immunoglobulin genes in Rev1-deficient mice. *J. Exp. Med.* 203:319-323.
52. Jansen, J. G. , A. Tsaalbi-Shtylik, G. Hendriks, H. Gali, A. Hendel, F. Johansson, K. Erixon, Z. Livneh, L. H. Mullenders, L. Haracska, and W. N. de. 2009. Separate domains of Rev1 mediate two modes of DNA damage bypass in mammalian cells. *Mol. Cell Biol.* 29:3113-3123.
 53. Jansen, J. G. , A. Tsaalbi-Shtylik, P. Langerak, F. Calleja, C. M. Meijers, H. Jacobs, and W. N. de. 2005. The BRCT domain of mammalian Rev1 is involved in regulating DNA translesion synthesis. *Nucleic Acids Res.* 33:356-365.
 54. Jiricny, J. 1998. Replication errors: cha(lle)nging the genome. *EMBO J.* 17:6427-6436.
 55. Johnson, R. E. , S. T. Henderson, T. D. Petes, S. Prakash, M. Bankmann, and L. Prakash. 1992. Saccharomyces cerevisiae RAD5-encoded DNA repair protein contains DNA helicase and zinc-binding sequence motifs and affects the stability of simple repetitive sequences in the genome. *Mol. Cell Biol.* 12:3807-3818.
 56. Johnson, R. E. , S. Prakash, and L. Prakash. 1999. Efficient bypass of a thymine-thymine dimer by yeast DNA polymerase, Poleta. *Science* 283:1001-1004.
 57. Johnson, R. E. , M. T. Washington, L. Haracska, S. Prakash, and L. Prakash. 2000. Eukaryotic polymerases iota and zeta act sequentially to bypass DNA lesions. *Nature* 406:1015-1019.
 58. Kadyrov, F. A. , L. Dzantiev, N. Constantin, and P. Modrich. 2006. Endonucleolytic function of MutLalpha in human mismatch repair. *Cell* 126:297-308.
 59. Kai, M. and T. S. Wang. 2003. Checkpoint activation regulates mutagenic translesion synthesis. *Genes Dev.* 17:64-76.
 60. Kajiwara, K. , J. Wang, T. Sakurai, S. Yamashita, M. Tanaka, M. Sato, M. Tagawa, E. Sugaya, K. Nakamura, K. Nakao, M. Katsuki, and M. Kimura. 2001. Sez4 gene encoding an elongation subunit of DNA polymerase zeta is required for normal embryogenesis. *Genes Cells* 6:99-106.
 61. Kannouche, P. L. , J. Wing, and A. R. Lehmann. 2004. Interaction of human DNA polymerase eta with monoubiquitinated PCNA: a possible mechanism for the polymerase switch in response to DNA damage. *Mol. Cell* 14:491-500.
 62. Kawamura, K. , J. Wang, R. Bahar, N. Koshikawa, T. Shishikura, A. Nakagawara, S. Sakiyama, K. Kajiwara, M. Kimura, and M. Tagawa. 2001. The error-prone DNA polymerase zeta catalytic subunit (Rev3) gene is ubiquitously expressed in normal and malignant human tissues. *Int. J. Oncol.* 18:97-103.
 63. Kee, Y. and A. D. D'Andrea. 2010. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. *Genes Dev* 24:1680-1694.
 64. Knipscheer, P. , M. Raschle, A. Smogorzewska, M. Enoiu, T. V. Ho, O. D. Scharer, S. J. Elledge, and J. C. Walter. 2009. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. *Science* 326:1698-1701.
 65. Kobayashi, M. , A. Hirano, T. Kumano, S. L. Xiang, K. Mihara, Y. Haseda, O. Matsui, H. Shimizu, and K. Yamamoto. 2004. Critical role for chicken Rad17 and Rad9 in the cellular response to DNA damage and stalled DNA replication. *Genes Cells* 9:291-303.
 66. Krijger, P. H. , P. Langerak, P. C. van den Berk, and H. Jacobs. 2009. Dependence of nucleotide substitutions on Ung2, Msh2, and PCNA-Ub during somatic hypermutation. *J. Exp. Med.* 206:2603-2611.
 67. Krokan, H. E. , F. Drablos, and G. Slupphaug. 2002. Uracil in DNA--occurrence, consequences and repair. *Oncogene* 21:8935-8948.
 68. Kunkel, T. A. 1985. The mutational specificity of DNA polymerase-beta during in vitro DNA synthesis. Production of frameshift, base substitution, and deletion mutations. *J. Biol. Chem.* 260:5787-5796.

69. Langerak, P. , A. O. Nygren, P. H. Krijger, P. C. van den Berk, and H. Jacobs. 2007. A/T mutagenesis in hypermutated immunoglobulin genes strongly depends on PCNAK164 modification. *J. Exp. Med.* 204:1989-1998.
70. Larsen, E. , L. Kleppa, T. J. Meza, L. A. Meza-Zepeda, C. Rada, C. G. Castellanos, G. F. Lien, G. J. Nesse, M. S. Neuberger, J. K. Laerdahl, D. R. William, and A. Klungland. 2008. Early-onset lymphoma and extensive embryonic apoptosis in two domain-specific Fen1 mice mutants. *Cancer Res.* 68:4571-4579.
71. Larson, E. D. , W. J. Cummings, D. W. Bednarski, and N. Maizels. 2005. MRE11/RAD50 cleaves DNA in the AID/UNG-dependent pathway of immunoglobulin gene diversification. *Mol. Cell* 20:367-375.
72. Lawrence, C. W. 2002. Cellular roles of DNA polymerase zeta and Rev1 protein. *DNA Repair (Amst)* 1:425-435.
73. Lawrence, C. W. and R. Christensen. 1976. UV mutagenesis in radiation-sensitive strains of yeast. *Genetics* 82:207-232.
74. Lederberg, J. 1959. Genes and antibodies. *Science* 129:1649-1653.
75. Lemontt, J. F. 1971. Mutants of yeast defective in mutation induced by ultraviolet light. *Genetics* 68:21-33.
76. Li, Z. , W. Xiao, J. J. McCormick, and V. M. Maher. 2002. Identification of a protein essential for a major pathway used by human cells to avoid UV-induced DNA damage. *Proc. Natl. Acad. Sci. U. S. A* 99:4459-4464.
77. Lin, W. , H. Xin, Y. Zhang, X. Wu, F. Yuan, and Z. Wang. 1999. The human REV1 gene codes for a DNA template-dependent dCMP transferase. *Nucleic Acids Res.* 27:4468-4475.
78. Lucas, D. , L. T. Lain de, M. A. Gonzalez, J. F. Ruiz, O. Dominguez, J. C. Casanova, A. Martinez, L. Blanco, and A. Bernad. 2005. Polymerase mu is up-regulated during the T cell-dependent immune response and its deficiency alters developmental dynamics of spleen centroblasts. *Eur. J. Immunol.* 35:1601-1611.
79. Marini, F. , N. Kim, A. Schuffert, and R. D. Wood. 2003. POLN, a nuclear PolA family DNA polymerase homologous to the DNA cross-link sensitivity protein Mus308. *J. Biol. Chem.* 278:32014-32019.
80. Marini, V. and L. Krejci. 2010. Srs2: the "Odd-Job Man" in DNA repair. *DNA Repair (Amst)* 9:268-275.
81. Martomo, S. A. , H. Saribasak, M. Yokoi, F. Hanaoka, and P. J. Gearhart. 2008. Reevaluation of the role of DNA polymerase theta in somatic hypermutation of immunoglobulin genes. *DNA Repair (Amst)* 7:1603-1608.
82. Martomo, S. A. , W. W. Yang, and P. J. Gearhart. 2004. A role for Msh6 but not Msh3 in somatic hypermutation and class switch recombination. *J. Exp. Med.* 200:61-68.
83. Martomo, S. A. , W. W. Yang, R. P. Wersto, T. Ohkumo, Y. Kondo, M. Yokoi, C. Masutani, F. Hanaoka, and P. J. Gearhart. 2005. Different mutation signatures in DNA polymerase eta- and MSH6-deficient mice suggest separate roles in antibody diversification. *Proc. Natl. Acad. Sci. U. S. A* 102:8656-8661.
84. Masuda, K. , R. Ouchida, M. Hikida, M. Nakayama, O. Ohara, T. Kurosaki, and J. Wang. 2006. Absence of DNA polymerase theta results in decreased somatic hypermutation frequency and altered mutation patterns in Ig genes. *DNA Repair (Amst)* 5:1384-1391.
85. Masuda, K. , R. Ouchida, Y. Li, X. Gao, H. Mori, and J. Y. Wang. 2009. A critical role for REV1 in regulating the induction of C:G transitions and A:T mutations during Ig gene hypermutation. *J Immunol* 183:1846-1850.
86. Masuda, K. , R. Ouchida, A. Takeuchi, T. Saito, H. Koseki, K. Kawamura, M. Tagawa, T. Tokuhisa, T. Azuma, and J. Wang. 2005. DNA polymerase theta contributes to the generation of C/G mutations during somatic hypermutation of Ig genes. *Proc. Natl. Acad. Sci. U. S. A* 102:13986-13991.
87. Masuda, Y. , M. Takahashi, S. Fukuda, M. Sumii, and K. Kamiya. 2002. Mechanisms of dCMP transferase re-

- actions catalyzed by mouse Rev1 protein. *J. Biol. Chem.* 277:3040-3046.
88. Masuda, Y. , M. Takahashi, N. Tsunekuni, T. Minami, M. Sumii, K. Miyagawa, and K. Kamiya. 2001. Deoxycytidyl transferase activity of the human REV1 protein is closely associated with the conserved polymerase domain. *J. Biol. Chem.* 276:15051-15058.
 89. Masutani, C. , R. Kusumoto, A. Yamada, N. Dohmae, M. Yokoi, M. Yuasa, M. Araki, S. Iwai, K. Takio, and F. Hanaoka. 1999a. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. *Nature* 399:700-704.
 90. Masutani, C. , R. Kusumoto, A. Yamada, N. Dohmae, M. Yokoi, M. Yuasa, M. Araki, S. Iwai, K. Takio, and F. Hanaoka. 1999b. The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta. *Nature* 399:700-704.
 91. Matsuda, T. , K. Bebenek, C. Masutani, F. Hanaoka, and T. A. Kunkel. 2000. Low fidelity DNA synthesis by human DNA polymerase-eta. *Nature* 404:1011-1013.
 92. McCulloch, S. D. , R. J. Kokoska, C. Masutani, S. Iwai, F. Hanaoka, and T. A. Kunkel. 2004a. Preferential cis-syn thymine dimer bypass by DNA polymerase eta occurs with biased fidelity. *Nature* 428:97-100.
 93. McCulloch, S. D. , R. J. Kokoska, C. Masutani, S. Iwai, F. Hanaoka, and T. A. Kunkel. 2004b. Preferential cis-syn thymine dimer bypass by DNA polymerase eta occurs with biased fidelity. *Nature* 428:97-100.
 94. McDonald, J. P. , A. S. Levine, and R. Woodgate. 1997. The *Saccharomyces cerevisiae* RAD30 gene, a homologue of *Escherichia coli* dinB and umuC, is DNA damage inducible and functions in a novel error-free postreplication repair mechanism. *Genetics* 147:1557-1568.
 95. Milstein, C. , M. S. Neuberger, and R. Staden. 1998. Both DNA strands of antibody genes are hypermutation targets. *Proc. Natl. Acad. Sci. U. S. A* 95:8791-8794.
 96. Modrich, P. 2006. Mechanisms in eukaryotic mismatch repair. *J. Biol. Chem.* 281:30305-30309.
 97. Moldovan, G. L. , B. Pfander, and S. Jentsch. 2007. PCNA, the maestro of the replication fork. *Cell* 129:665-679.
 98. Motegi, A. , H. J. Liaw, K. Y. Lee, H. P. Roest, A. Maas, X. Wu, H. Moinova, S. D. Markowitz, H. Ding, J. H. Hoeijmakers, and K. Myung. 2008. Polyubiquitination of proliferating cell nuclear antigen by HLTF and SHPRH prevents genomic instability from stalled replication forks. *Proc. Natl. Acad. Sci. U. S. A* 105:12411-12416.
 99. Motegi, A. , R. Sood, H. Moinova, S. D. Markowitz, P. P. Liu, and K. Myung. 2006. Human SHPRH suppresses genomic instability through proliferating cell nuclear antigen polyubiquitination. *J. Cell Biol.* 175:703-708.
 100. Murakumo, Y. , Y. Ogura, H. Ishii, S. Numata, M. Ichihara, C. M. Croce, R. Fishel, and M. Takahashi. 2001. Interactions in the error-prone postreplication repair proteins hREV1, hREV3, and hREV7. *J. Biol. Chem.* 276:35644-35651.
 101. Muramatsu, M. , K. Kinoshita, S. Fagarasan, S. Yamada, Y. Shinkai, and T. Honjo. 2000. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. *Cell* 102:553-563.
 102. Nelson, A. L. , E. Dhimolea, and J. M. Reichert. 2010. Development trends for human monoclonal antibody therapeutics. *Nat. Rev. Drug Discov.* 9:767-774.
 103. Nelson, J. R. , P. E. Gibbs, A. M. Nowicka, D. C. Hinkle, and C. W. Lawrence. 2000. Evidence for a second function for *Saccharomyces cerevisiae* Rev1p. *Mol. Microbiol.* 37:549-554.
 104. Nelson, J. R. , C. W. Lawrence, and D. C. Hinkle. 1996. Deoxycytidyl transferase activity of yeast REV1 protein. *Nature* 382:729-731.
 105. Neuberger, M. S. 2008. Antibody diversification by somatic mutation: from Burnet onwards. *Immunol. Cell Biol.* 86:124-132.

106. Niedzwiedz, W. , G. Mosedale, M. Johnson, C. Y. Ong, P. Pace, and K. J. Patel. 2004. The Fanconi anaemia gene FANCC promotes homologous recombination and error-prone DNA repair. *Mol Cell* 15:607-620.
107. Niimi, A. , S. Brown, S. Sabbioneda, P. L. Kannouche, A. Scott, A. Yasui, C. M. Green, and A. R. Lehmann. 2008. Regulation of proliferating cell nuclear antigen ubiquitination in mammalian cells. *Proc Natl Acad Sci U S A* 105:16125-16130.
108. Ogi, T. and A. R. Lehmann. 2006. The Y-family DNA polymerase kappa (pol kappa) functions in mammalian nucleotide-excision repair. *Nat. Cell Biol.* 8:640-642.
109. Ogi, T. , S. Limsirichaikul, R. M. Overmeer, M. Volker, K. Takenaka, R. Cloney, Y. Nakazawa, A. Niimi, Y. Miki, N. G. Jaspers, L. H. Mullenders, S. Yamashita, M. I. Foustieri, and A. R. Lehmann. 2010. Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. *Mol. Cell* 37:714-727.
110. Ogi, T. , Y. Shinkai, K. Tanaka, and H. Ohmori. 2002. Polkappa protects mammalian cells against the lethal and mutagenic effects of benzo[a]pyrene. *Proc. Natl. Acad. Sci. U. S. A* 99:15548-15553.
111. Ohashi, E. , K. Bebenek, T. Matsuda, W. J. Feaver, V. L. Gerlach, E. C. Friedberg, H. Ohmori, and T. A. Kunkel. 2000. Fidelity and processivity of DNA synthesis by DNA polymerase kappa, the product of the human DINB1 gene. *J. Biol. Chem.* 275:39678-39684.
112. Ohashi, E. , Y. Murakumo, N. Kanjo, J. Akagi, C. Masutani, F. Hanaoka, and H. Ohmori. 2004. Interaction of hREV1 with three human Y-family DNA polymerases. *Genes Cells* 9:523-531.
113. Ohkumo, T. , Y. Kondo, M. Yokoi, T. Tsukamoto, A. Yamada, T. Sugimoto, R. Kanao, Y. Higashi, H. Kondoh, M. Tatematsu, C. Masutani, and F. Hanaoka. 2006. UV-B radiation induces epithelial tumors in mice lacking DNA polymerase eta and mesenchymal tumors in mice deficient for DNA polymerase iota. *Mol. Cell Biol.* 26:7696-7706.
114. Papouli, E. , S. Chen, A. A. Davies, D. Huttner, L. Krejci, P. Sung, and H. D. Ulrich. 2005. Crosstalk between SUMO and ubiquitin on PCNA is mediated by recruitment of the helicase Srs2p. *Mol. Cell* 19:123-133.
115. Parrilla-Castellar, E. R. , S. J. Arlander, and L. Karnitz. 2004. Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex. *DNA Repair (Amst)* 3:1009-1014.
116. Petersen-Mahrt, S. K. , R. S. Harris, and M. S. Neuberger. 2002. AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. *Nature* 418:99-103.
117. Petta, T. B. , S. Nakajima, A. Zlatanou, E. Despras, S. Couve-Privat, A. Ishchenko, A. Sarasin, A. Yasui, and P. Kannouche. 2008. Human DNA polymerase iota protects cells against oxidative stress. *EMBO J.* 27:2883-2895.
118. Pfander, B. , G. L. Moldovan, M. Sacher, C. Hoege, and S. Jentsch. 2005. SUMO-modified PCNA recruits Srs2 to prevent recombination during S phase. *Nature* 436:428-433.
119. Pham, P. , R. Bransteitter, J. Petruska, and M. F. Goodman. 2003. Processive AID-catalysed cytosine deamination on single-stranded DNA simulates somatic hypermutation. *Nature* 424:103-107.
120. Phung, Q. H. , D. B. Winter, R. Alrefai, and P. J. Gearhart. 1999. Hypermutation in Ig V genes from mice deficient in the MLH1 mismatch repair protein. *J. Immunol.* 162:3121-3124.
121. Phung, Q. H. , D. B. Winter, A. Cranston, R. E. Tarone, V. A. Bohr, R. Fishel, and P. J. Gearhart. 1998. Increased hypermutation at G and C nucleotides in immunoglobulin variable genes from mice deficient in the MSH2 mismatch repair protein. *J. Exp. Med.* 187:1745-1751.
122. Plosky, B. S. , A. E. Vidal, A. R. Fernandez de Henestrosa, M. P. McLennigan, J. P. McDonald, S. Mead, and R.

- Woodgate. 2006. Controlling the subcellular localization of DNA polymerases ι and η via interactions with ubiquitin. *EMBO J* 25:2847-2855.
123. Podlutzky, A. J. , I. I. Dianova, V. N. Podust, V. A. Bohr, and G. L. Dianov. 2001. Human DNA polymerase β initiates DNA synthesis during long-patch repair of reduced AP sites in DNA. *EMBO J*. 20:1477-1482.
124. Prakash, S. , R. E. Johnson, and L. Prakash. 2005. Eukaryotic translesion synthesis DNA polymerases: specificity of structure and function. *Annu. Rev. Biochem.* 74:317-353.
125. Quah, S. K. , R. C. von Borstel, and P. J. Hastings. 1980. The origin of spontaneous mutation in *Saccharomyces cerevisiae*. *Genetics* 96:819-839.
126. Rada, C. , J. M. Di Noia, and M. S. Neuberger. 2004. Mismatch recognition and uracil excision provide complementary paths to both Ig switching and the A/T-focused phase of somatic mutation. *Mol. Cell* 16:163-171.
127. Rada, C. , M. R. Ehrenstein, M. S. Neuberger, and C. Milstein. 1998. Hot spot focusing of somatic hypermutation in MSH2-deficient mice suggests two stages of mutational targeting. *Immunity*. 9:135-141.
128. Rada, C. , G. T. Williams, H. Nilsen, D. E. Barnes, T. Lindahl, and M. S. Neuberger. 2002. Immunoglobulin isotype switching is inhibited and somatic hypermutation perturbed in UNG-deficient mice. *Curr. Biol.* 12:1748-1755.
129. Rajewsky, K. 1996. Clonal selection and learning in the antibody system. *Nature* 381:751-758.
130. Ramiro, A. R. , P. Stavropoulos, M. Jankovic, and M. C. Nussenzweig. 2003. Transcription enhances AID-mediated cytidine deamination by exposing single-stranded DNA on the nontemplate strand. *Nat. Immunol.* 4:452-456.
131. Roa, S. , E. Avdievich, J. U. Peled, T. MacCarthy, U. Werling, F. L. Kuang, R. Kan, C. Zhao, A. Bergman, P. E. Cohen, W. Edelmann, and M. D. Scharff. 2008. Ubiquitylated PCNA plays a role in somatic hypermutation and class-switch recombination and is required for meiotic progression. *Proc. Natl. Acad. Sci. U. S. A* 105:16248-16253.
132. Rogozin, I. B. and N. A. Kolchanov. 1992. Somatic hypermutagenesis in immunoglobulin genes. II. Influence of neighbouring base sequences on mutagenesis. *Biochim. Biophys. Acta* 1171:11-18.
133. Rogozin, I. B. , Y. I. Pavlov, K. Bebenek, T. Matsuda, and T. A. Kunkel. 2001. Somatic mutation hotspots correlate with DNA polymerase η error spectrum. *Nat. Immunol.* 2:530-536.
134. Ross, A. L. and J. E. Sale. 2006. The catalytic activity of REV1 is employed during immunoglobulin gene diversification in DT40. *Mol. Immunol.* 43:1587-1594.
135. Ross, A. L. , L. J. Simpson, and J. E. Sale. 2005. Vertebrate DNA damage tolerance requires the C-terminus but not BRCT or transferase domains of REV1. *Nucleic Acids Res.* 33:1280-1289.
136. Sabbioneda, S. , A. M. Gourdin, C. M. Green, A. Zotter, G. Giglia-Mari, A. Houtsmuller, W. Vermeulen, and A. R. Lehmann. 2008. Effect of proliferating cell nuclear antigen ubiquitination and chromatin structure on the dynamic properties of the Y-family DNA polymerases. *Mol. Biol. Cell* 19:5193-5202.
137. Sabbioneda, S. , B. K. Minesinger, M. Giannattasio, P. Plevani, M. Muzi-Falconi, and S. Jinks-Robertson. 2005. The 9-1-1 checkpoint clamp physically interacts with polzeta and is partially required for spontaneous polzeta-dependent mutagenesis in *Saccharomyces cerevisiae*. *J. Biol. Chem.* 280:38657-38665.
138. Schanz, S. , D. Castor, F. Fischer, and J. Jiricny. 2009. Interference of mismatch and base excision repair during the processing of adjacent U/G mispairs may play a key role in somatic hypermutation. *Proc. Natl. Acad. Sci. U. S. A* 106:5593-5598.
139. Schenten, D. , V. L. Gerlach, C. Guo, S. Velasco-Miguel, C. L. Hladik, C. L. White, E. C. Friedberg, K. Rajewsky,

- and G. Esposito. 2002. DNA polymerase kappa deficiency does not affect somatic hypermutation in mice. *Eur. J. Immunol.* 32:3152-3160.
140. Schenten, D. , S. Kracker, G. Esposito, S. Franco, U. Klein, M. Murphy, F. W. Alt, and K. Rajewsky. 2009. Pol zeta ablation in B cells impairs the germinal center reaction, class switch recombination, DNA break repair, and genome stability. *J. Exp. Med.* 206:477-490.
141. Schmutz, V. , R. Janel-Bintz, J. Wagner, D. Biard, N. Shiomi, R. P. Fuchs, and A. M. Cordonnier. 2010. Role of the ubiquitin-binding domain of Poleta in Rad18-independent translesion DNA synthesis in human cell extracts. *Nucleic Acids Res.* 38:6456-6465.
142. Seki, M. , C. Masutani, L. W. Yang, A. Schuffert, S. Iwai, I. Bahar, and R. D. Wood. 2004. High-efficiency bypass of DNA damage by human DNA polymerase Q. *EMBO J.* 23:4484-4494.
143. Shachar, S. , O. Ziv, S. Avkin, S. Adar, J. Wittschieben, T. Reissner, S. Chaney, E. C. Friedberg, Z. Wang, T. Carell, N. Geacintov, and Z. Livneh. 2009. Two-polymerase mechanisms dictate error-free and error-prone translesion DNA synthesis in mammals. *EMBO J.* 28:383-393.
144. Shen, H. M. , A. Tanaka, G. Bozek, D. Nicolae, and U. Storb. 2006. Somatic hypermutation and class switch recombination in Msh6(-/-)Ung(-/-) double-knockout mice. *J. Immunol.* 177:5386-5392.
145. Silverstein, A. M. 1985. A history of theories of antibody formation. *Cell Immunol.* 91:263-283.
146. Simpson, L. J. and J. E. Sale. 2003. Rev1 is essential for DNA damage tolerance and non-templated immunoglobulin gene mutation in a vertebrate cell line. *EMBO J.* 22:1654-1664.
147. Singhal, R. K. and S. H. Wilson. 1993. Short gap-filling synthesis by DNA polymerase beta is processive. *J. Biol. Chem.* 268:15906-15911.
148. Sonoda, E. , T. Okada, G. Y. Zhao, S. Tateishi, K. Araki, M. Yamaizumi, T. Yagi, N. S. Verkaik, G. van, M. Takata, and S. Takeda. 2003. Multiple roles of Rev3, the catalytic subunit of polzeta in maintaining genome stability in vertebrates. *EMBO J.* 22:3188-3197.
149. Stavnezer, J. , J. E. Guikema, and C. E. Schrader. 2008. Mechanism and regulation of class switch recombination. *Annu. Rev. Immunol.* 26:261-292.
150. Stelter, P. and H. D. Ulrich. 2003. Control of spontaneous and damage-induced mutagenesis by SUMO and ubiquitin conjugation. *Nature* 425:188-191.
151. Tissier, A. , E. G. Frank, J. P. McDonald, S. Iwai, F. Hanaoka, and R. Woodgate. 2000. Misinsertion and bypass of thymine-thymine dimers by human DNA polymerase iota. *EMBO J.* 19:5259-5266.
152. Tonegawa, S. 1983. Somatic generation of antibody diversity. *Nature* 302:575-581.
153. Unk, I. , I. Hajdu, K. Fatyol, J. Hurwitz, J. H. Yoon, L. Prakash, S. Prakash, and L. Haracska. 2008. Human HLTf functions as a ubiquitin ligase for proliferating cell nuclear antigen polyubiquitination. *Proc. Natl. Acad. Sci. U. S. A* 105:3768-3773.
154. Unk, I. , I. Hajdu, K. Fatyol, B. Szakal, A. Blastyak, V. Bermudez, J. Hurwitz, L. Prakash, S. Prakash, and L. Haracska. 2006. Human SHPRH is a ubiquitin ligase for Mms2-Ubc13-dependent polyubiquitylation of proliferating cell nuclear antigen. *Proc. Natl. Acad. Sci. U. S. A* 103:18107-18112.
155. Vaisman, A. , C. Masutani, F. Hanaoka, and S. G. Chaney. 2000. Efficient translesion replication past oxaliplatin and cisplatin GpG adducts by human DNA polymerase eta. *Biochemistry* 39:4575-4580.
156. Van Sloun, P. P. , I. Varlet, E. Sonneveld, J. J. Boei, R. J. Romeijn, J. C. Eeken, and W. N. de. 2002. Involvement of mouse Rev3 in tolerance of endogenous and exogenous DNA damage. *Mol. Cell Biol.* 22:2159-2169.
157. Victora, G. D. , T. A. Schwickert, D. R. Fooksman, A. O. Kamphorst, M. Meyer-Hermann, M. L. Dustin, and M. C. Nussenzweig. 2010. Germinal center

- dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. *Cell* 143:592-605.
158. Volkmer, E. and L. M. Karnitz. 1999. Human homologs of *Schizosaccharomyces pombe* rad1, hus1, and rad9 form a DNA damage-responsive protein complex. *J. Biol. Chem.* 274:567-570.
 159. Wang, J. , K. Kajiwara, K. Kawamura, M. Kimura, H. Miyagishima, H. Koseki, and M. Tagawa. 2002. An essential role for REV3 in mammalian cell survival: absence of REV3 induces p53-independent embryonic death. *Biochem. Biophys. Res. Commun.* 293:1132-1137.
 160. Washington, M. T. , R. E. Johnson, L. Prakash, and S. Prakash. 2002. Human DINB1-encoded DNA polymerase kappa is a promiscuous extender of mispaired primer termini. *Proc. Natl. Acad. Sci. U. S. A* 99:1910-1914.
 161. Watanabe, K. , S. Tateishi, M. Kawasaki, T. Tsurimoto, H. Inoue, and M. Yamaizumi. 2004. Rad18 guides poleta to replication stalling sites through physical interaction and PCNA monoubiquitination. *EMBO J.* 23:3886-3896.
 162. Weiss, R. S. , T. Enoch, and P. Leder. 2000. Inactivation of mouse Hus1 results in genomic instability and impaired responses to genotoxic stress. *Genes Dev.* 14:1886-1898.
 163. Wiesendanger, M. , B. Kneitz, W. Edelmann, and M. D. Scharff. 2000. Somatic hypermutation in MutS homologue (MSH)3-, MSH6-, and MSH3/MSH6-deficient mice reveals a role for the MSH2-MSH6 heterodimer in modulating the base substitution pattern. *J. Exp. Med.* 191:579-584.
 164. Wilson, T. M. , A. Vaisman, S. A. Martomo, P. Sullivan, L. Lan, F. Hanaoka, A. Yasui, R. Woodgate, and P. J. Gearhart. 2005. MSH2-MSH6 stimulates DNA polymerase eta, suggesting a role for A:T mutations in antibody genes. *J. Exp. Med.* 201:637-645.
 165. Winter, D. B. , Q. H. Phung, A. Umar, S. M. Baker, R. E. Tarone, K. Tanaka, R. M. Liskay, T. A. Kunkel, V. A. Bohr, and P. J. Gearhart. 1998. Altered spectra of hypermutation in antibodies from mice deficient for the DNA mismatch repair protein PMS2. *Proc. Natl. Acad. Sci. U. S. A* 95:6953-6958.
 166. Xanthoudakis, S. , R. J. Smeyne, J. D. Wallace, and T. Curran. 1996. The redox/DNA repair protein, Ref-1, is essential for early embryonic development in mice. *Proc. Natl. Acad. Sci. U. S. A* 93:8919-8923.
 167. Yabuki, M. , M. M. Fujii, and N. Maizels. 2005. The MRE11-RAD50-NBS1 complex accelerates somatic hypermutation and gene conversion of immunoglobulin variable regions. *Nat. Immunol.* 6:730-736.
 168. Yamamoto, K. , S. Hirano, M. Ishiai, K. Morishima, H. Kitao, K. Namikoshi, M. Kimura, N. Matsushita, H. Arakawa, J. M. Buerstedde, K. Komatsu, L. H. Thompson, and M. Takata. 2005. Fanconi anemia protein FANCD2 promotes immunoglobulin gene conversion and DNA repair through a mechanism related to homologous recombination. *Mol Cell Biol* 25:34-43.
 169. Yoon, J. H. , L. Prakash, and S. Prakash. 2010. Error-free replicative bypass of (6-4) photoproducts by DNA polymerase zeta in mouse and human cells. *Genes Dev.* 24:123-128.
 170. Yu, X. , C. C. Chini, M. He, G. Mer, and J. Chen. 2003. The BRCT domain is a phospho-protein binding domain. *Science* 302:639-642.
 171. Zan, H. , N. Shima, Z. Xu, A. Al-Qahtani, A. J. Evinger lii, Y. Zhong, J. C. Schimenti, and P. Casali. 2005. The translesion DNA polymerase theta plays a dominant role in immunoglobulin gene somatic hypermutation. *EMBO J.* 24:3757-3769.
 172. Zeng, X. , D. B. Winter, C. Kasper, K. H. Kraemer, A. R. Lehmann, and P. J. Gearhart. 2001. DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. *Nat. Immunol.* 2:537-541.
 173. Zhang, Y. , F. Yuan, X. Wu, M. Wang, O. Rechkoblit, J. S. Taylor, N. E. Geacintov, and Z. Wang. 2000. Error-free and error-prone lesion bypass by human DNA polymerase kappa in vitro. *Nucleic Acids Res.* 28:4138-4146.

174. Ziv, O. , N. Geacintov, S. Nakajima, A. Yasui, and Z. Livneh. 2009. DNA polymerase zeta cooperates with polymerases kappa and iota in transle-

sion DNA synthesis across pyrimidine photodimers in cells from XPV patients. *Proc. Natl. Acad. Sci. U. S. A* 106:11552-11557.

